Mesenchymal stem cell differentiation
The present invention provides for methods and compositions for treating or preventing arthritis and joint injury.
1. A polypeptide consisting of SEQ ID NO: 5, wherein the polypeptide is PEGylated.
2. A pharmaceutical composition comprising an effective amount of the polypeptide of claim 1 .
3. The pharmaceutical composition of claim 2 , further comprising a buffer.
4. The pharmaceutical composition of claim 2 , further comprising hyaluronic acid.
5. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is suitable for intra-articular delivery.
6. A pharmaceutical composition comprising a polypeptide consisting of SEQ ID NO: 5, and a preservative.
7. The polypeptide of claim 1 , wherein the polypeptide has chondrogenic activity and reduced ability to increase triglyceridemia.
8. The polypeptide of claim 1 , wherein the polypeptide has reduced heterogeneous glycosylation relative to a naturally-occurring human ANGPTL3 protein.
9. A fusion protein comprising a polypeptide consisting of SEQ ID NO: 5 fused to a human serum albumin (HSA), an immunoglobulin heavy chain constant region (Fc), a polyhistidine, a glutathione S transferase (GST), a thioredoxin, a protein A, a protein G, or a maltose binding protein (MBP).
10. A pharmaceutical composition comprising an effective amount of the fusion protein of claim 9 .
11. The pharmaceutical composition of claim 10 , further comprising a buffer.
12. The pharmaceutical composition of claim 10 , further comprising hyaluronic acid.
13. The pharmaceutical composition of claim 10 , wherein the pharmaceutical composition is suitable for intra-articular delivery.